No association of malignant B‐cell non‐Hodgkin lymphomas with ipsilateral SARS‐CoV‐2 vaccination
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5687
Abstract: SARS‐CoV‐2 vaccines cause acute ipsilateral lymph node swelling in an important proportion of vaccines. Thus far, no malignant lymphadenopathies have been reported in temporal context to vaccination in the ipsilateral draining lymph node areas. read more here.
Keywords: non hodgkin; vaccination; association malignant; cell non ... See more keywords
Effect of body mass index on the prognosis of children and adolescents with high‐grade mature B‐cell non‐Hodgkin lymphoma
Sign Up to like & getrecommendations! Published in 2024 at "Cancer"
DOI: 10.1002/cncr.35536
Abstract: Little progress has been made in determining the prognostic factors for children and adolescents with high‐grade mature B‐cell non‐Hodgkin lymphoma (HG B‐NHL). Based on the important role of body mass index (BMI) in cancer, this… read more here.
Keywords: high grade; adolescents high; cell non; children adolescents ... See more keywords
Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B‐Cell Non‐Hodgkin's Lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1133
Abstract: The pharmacokinetics (PK) and safety of ofatumumab and bendamustine alone and in combination were evaluated in patients with treatment‐naive or relapsed indolent B‐cell non‐Hodgkin lymphoma (iNHL). Patients were randomly assigned to ofatumumab and bendamustine or… read more here.
Keywords: hodgkin lymphoma; non hodgkin; indolent cell; concentration ... See more keywords
Cell Non-autonomous UPRER Signaling.
Sign Up to like & getrecommendations! Published in 2018 at "Current topics in microbiology and immunology"
DOI: 10.1007/82_2017_38
Abstract: The UPRER is an important regulator of secretory pathway homeostasis, and plays roles in many physiological processes. Its broad range of targets and ability to modulate secretion and membrane trafficking make it perfectly positioned to… read more here.
Keywords: cell non; non autonomous; autonomous uprer; uprer ... See more keywords
Concentration and Glycoform of Rituximab in Plasma of Patients with B Cell Non-Hodgkin’s Lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "Pharmaceutical Research"
DOI: 10.1007/s11095-019-2624-5
Abstract: PurposeTherapeutic antibodies have heterogeneities in their structures, although its structural alteration in the body is unclear. Here, we analyzed the change of amino acid modifications and carbohydrate chains of rituximab after administration to patients.MethodsTwenty B… read more here.
Keywords: rituximab; cell non; plasma; hodgkin lymphoma ... See more keywords
The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL)
Sign Up to like & getrecommendations! Published in 2022 at "Current Treatment Options in Oncology"
DOI: 10.1007/s11864-021-00932-2
Abstract: Natural killer (NK) cells have played a critical—if largely unrecognized or ignored—role in the treatment of B cell non-Hodgkin lymphoma (NHL) since the introduction of CD20-directed immunotherapy with rituximab as a cornerstone of therapy over… read more here.
Keywords: natural killer; cell nhl; hodgkin lymphoma; cell ... See more keywords
DOS-3 mediates cell-non-autonomous DAF-16/FOXO activity in antagonizing age-related loss of C. elegans germline stem/progenitor cells
Sign Up to like & getrecommendations! Published in 2024 at "Nature Communications"
DOI: 10.1038/s41467-024-49318-6
Abstract: Age-related depletion of stem cells causes tissue degeneration and failure to tissue regeneration, driving aging at the organismal level. Previously we reported a cell-non-autonomous DAF-16/FOXO activity in antagonizing the age-related loss of germline stem/progenitor cells… read more here.
Keywords: daf foxo; non autonomous; stem; cell non ... See more keywords
Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2023.2171397
Abstract: ABSTRACT Introduction Chimeric antigen receptor T (CAR T) cell therapy epitomizes the success of T cell engineering. Today, it is an integral component of the treatment algorithm for various types of B-cell non-Hodgkin lymphoma (NHL).… read more here.
Keywords: cell; hodgkin lymphoma; non hodgkin; lymphoma ... See more keywords
RABR-1, an atypical Rab-related GTPase cell non-autonomously restricts somatosensory dendrite branching.
Sign Up to like & getrecommendations! Published in 2024 at "Genetics"
DOI: 10.1093/genetics/iyae113
Abstract: Neurons are highly polarized cells with dendrites and axons. Dendrites, which receive sensory information or input from other neurons, often display elaborately branched morphologies. While mechanisms that promote dendrite branching have been widely studied, less… read more here.
Keywords: rab; rabr; non autonomously; cell non ... See more keywords
Novel Mutations in SH2D1A Gene in X-linked Lymphoproliferative Syndrome, Diagnosed After B-Cell Non-Hodgkin Lymphoma
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000000815
Abstract: Background: X-linked lymphoproliferative disease type I (XLP I) is caused by mutations in the SH2D1A gene and characterized mainly by hypogammaglobulinemia and abnormal response to Epstein-Barr virus with a high predisposition to B-cell non-Hodgkin lymphoma… read more here.
Keywords: linked lymphoproliferative; lymphoma; cell non; hodgkin lymphoma ... See more keywords
A phase 1/2 trial of ublituximab, a novel anti‐CD20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Haematology"
DOI: 10.1111/bjh.14534
Abstract: This phase 1/2 study evaluated the safety, pharmacokinetic behavior and anti‐tumour activity of ublituximab, a unique type I, chimeric, glycoengineered anti‐CD20 monoclonal antibody, in rituximab‐relapsed or ‐refractory patients with B‐cell non‐Hodgkin lymphoma (B‐NHL) or chronic… read more here.
Keywords: cell non; anti cd20; cd20 monoclonal; non hodgkin ... See more keywords